Search clinical trials for: VX-659

Total 571 results

Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (AMPLITUDE)

Proteinuric Kidney Disease

United States, Spain, Ghana, France, United Kingdom, Belgium, Brazil, Colombia, Portugal, Canada, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Pain

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Alpha1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland, Sweden, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Cervical Spinal Cord Injury

United States, Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
Vertex Pharmaceuticals Incorporated

Completed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

Painful Lumbosacral Radiculopathy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-668

Alpha-1 Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-634

Alpha 1-Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Alpha 1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Small Fiber Neuropathy

United States, Netherlands, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Osteoarthritis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Vertex Pharmaceuticals Incorporated

Completed

VX-950 and Peginterferon for Hepatitis C

Hepatitis C

Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
University Hospital, Toulouse
Fondation Plan Alzheimer

Completed

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients (VIP)

Alzheimer Disease

France
EIP Pharma Inc
Voisin Consulting, Inc.

Terminated

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Huntington Disease

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Australia, France, Germany, Italy, Czechia, Austria, Sweden, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
EIP Pharma Inc
Amsterdam UMC, location VUmc; Worldwide Clinical Trials

Completed

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease (REVERSE-SD)

Alzheimer Disease

United States, Netherlands, United Kingdom, Czechia, Denmark
T3D Therapeutics, Inc.
National Institute on Aging (NIA); Alzheimer's Association; Clinilabs, Inc.

Completed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Alzheimer Disease

United States
University of California, Los Angeles
University of Iowa; Children's Hospital Colorado; University of Kansas Medical... and other collaborators

Recruiting

Sinus Disease in Young Children With Cystic Fibrosis

Chronic Rhinosinusitis (Diagnosis) | Cystic Fibrosis | Olfactory Disorder | Cystic Fibrosis in Children | Olfactory Impairment

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Belgium, Spain, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United Kingdom

Search clinical trials for: VX-659

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations